This slide show highlights some of the top stories of the month, including the approval of a new agent for RCC, a study that found declines in prostate cancer deaths have mirrored the declines in smoking rates, and more.
Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC
October 4th 2023Investigators will present overall survival and objective response data from the phase 3 MARIPOSA trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.
2 Clarke Drive
Cranbury, NJ 08512